Shipment Suspension
BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced that, effective August 7, it has suspended all orders and shipments of its ExoCR and BioX biocosmeceutical product lines. The suspension is described as part of an ongoing internal business review and regulatory assessment; the company has not indicated whether the products will be discontinued after the review.
Financial Position and Market Reaction
The company, incorporated in Nevada and headquartered in Melville, New York, has a market capitalization of approximately $5.61 million and generated $360,000 of revenue over the trailing twelve‑month period. Following the announcement, the stock has declined sharply, down about 81% year‑to‑date and 85% over the past twelve months.
Revolving Loan Agreement
In a separate development, BioRestorative entered into a revolving loan facility with Bowery Group LLC. The agreement permits the company to draw up to $1 million of principal, bearing interest at 12% per annum, which escalates to 16% per annum upon an event of default. The outstanding principal, together with any accrued interest, is due one year from the loan’s closing date, although pre‑payment is permitted without penalty.
Activist Stake Acquisition
Activist hedge fund Kaos Capital disclosed that it has acquired a 4.9% equity stake in BioRestorative through open‑market transactions. Kaos Capital has indicated its intention to seek a meeting with the company’s board to discuss potential strategic alternatives, including the exploration of artificial‑intelligence opportunities.
Regulatory Filing
All of the above disclosures were included in BioRestorative’s Form 8‑K filing with the U.S. Securities and Exchange Commission and were also communicated via a press release.